Investigational drug · Phase 2
Human umbilical cord blood-derived mesenchymal stem cells
Also called: SMUP-IA-01, mid-dose, PNEUMOSTEM
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Knee Osteoarthritis, Bronchopulmonary Dysplasia, BPD.
Phase 2Last checked: Nov 20, 2026Latest source record: Feb 7, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
32
Any phase or sponsor naming "Human umbilical cord blood-derived mesenchymal stem cells"
First trial start
2019
Jul 5, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Human umbilical cord blood-derived mesenchymal stem cells", any sponsor or status.
Conditions studied
As listed on its trial records.
- Knee Osteoarthritis
- Bronchopulmonary Dysplasia
- BPD
Approved drugs for the same conditions: Osteoarthritis
Largest trials
Live from ClinicalTrials.gov: studies naming "Human umbilical cord blood-derived mesenchymal stem cells" as an intervention, largest first.
- UC-MSC Infusion for HBV-Related Acute-on-Chronic Liver FailurePivotal-lookingStatus unknown
Sun Yat-sen UniversityAcademic, hospital or other
NCT02812121 · 261 participants (planned) · Start Jun 2016 · Primary completion Jun 2017
Drug: umbilical cord blood mesenchymal stem cells · For: Liver Failure
- Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of TalusPivotal-lookingCompleted
Hyundai Bioland Co., Ltd.Industry
NCT04310215 · 102 participants · Start Mar 3, 2020 · Primary completion Jun 13, 2022
Drug: CARTISTEM® · For: Chondral or Osteochondral Lesion of Talus
Sites: Seoul, South Korea; Daejeon, South Korea; Incheon, South Korea · 6 sites in all
- Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee OsteoarthritisCompleted
Medipost Co Ltd.Industry
NCT05182034 · 94 participants · Start Feb 24, 2022 · Primary completion Oct 17, 2023
Drug: SMUP-IA-01(low dose); SMUP-IA-01(mid dose) and 1 more · For: Knee Osteoarthritis
Sites: Gyeonggi-do, South Korea; Seoul, South Korea · 5 sites in all
Joanne Kurtzberg, MDAcademic, hospital or other
NCT03473301 · 91 participants · Start Apr 10, 2018 · Primary completion Feb 26, 2020
Drug: Infusion of allogeneic umbilical cord blood; Infusion of MSCs · For: Cerebral Palsy
Sites: Durham, North Carolina
- Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active ControlActive, not recruiting
Medipost Co Ltd.Industry
NCT06798727 · 84 participants · Start Mar 20, 2023 · Primary completion Mar 20, 2027
Drug: SMUP-IA-01(low-dose); SMUP-IA-01(mid-dose) and 1 more · For: Knee Osteoarthritis
Sites: Gyeonggi-do, South Korea; Seoul, South Korea · 5 sites in all
Medipost Co Ltd.Industry
NCT01828957 · 69 participants · Start Apr 2013 · Primary completion May 2015
Drug: Pneumostem® · For: Bronchopulmonary Dysplasia
Sites: Seoul, South Korea · 2 sites in all
Medipost Co Ltd.Industry
NCT01897987 · 62 participants · Start Jan 2014 · Primary completion Mar 2020
Drug: Pneumostem®; normal saline · For: Bronchopulmonary Dysplasia
Sites: Seoul, South Korea · 2 sites in all
- Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical TrialActive, not recruiting
Medipost Co Ltd.Industry
NCT04003857 · 60 participants (planned) · Start Jul 5, 2019 · Primary completion Jun 30, 2027
Drug: PNEUMOSTEM®; normal saline · For: Bronchopulmonary Dysplasia; BPD
Sites: Seoul, South Korea · 2 sites in all
Medipost Co Ltd.Industry
NCT03392467 · 60 participants · Start Aug 13, 2018 · Primary completion Jan 9, 2024
Drug: PNEUMOSTEM · For: Severe Bronchopulmonary Dysplasia
Sites: Seoul, South Korea · 2 sites in all
Qingdao UniversityAcademic, hospital or other
NCT01216865 · 50 participants (planned) · Start Jan 2011 · Primary completion Dec 2012
Drug: umbilical cord mesenchymal stem cells; Standard Therapy · For: Diabetic Foot; Critical Limb Ischemia; Mesenchymal Stem Cells and 1 more
Sites: Qingdao, China
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical safety evaluation of Vernolac, a commercially available polyherbal nutraceutical comprising Vernonia zeylanica, Nigella sativa, Hemidesmus indicus, Smilax glabra, and Leucas zeylanica, in Wistar rats.
Wijerathne SK, Epitawala Arachchige OV, De Vass Gunawardane S, et al. · PLoS One 2026
- Safety of Garcinia mangostana L. (mangosteen) peel extract as a novel food pursuant to Regulation (EU) 2015/2283.
Turck D, Bohn T, Cámara M, et al. · EFSA J 2026
- Effectiveness, safety and acceptability of mifepristone compared with other interventions in reproductive-age women using emergency contraception for the prevention of pregnancy: a systematic review and meta-analysis.
Ramanadhan S, Edelman A, Che Y, et al. · BMJ Sex Reprod Health 2026
- Safety and Immunogenicity of a PD-1-Enhanced HIV-1 Therapeutic DNA Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Trial in People With HIV-1 on Antiretroviral Therapy.
Peng Q, Wong YC, Cheng WY, et al. · J Infect Dis 2026
- Mifepristone versus other interventions for the prevention of pregnancy in reproductive-age women using emergency contraception.
Ramanadhan S, Edelman A, Che Y, et al. · Cochrane Database Syst Rev 2026
- Dimethyl itaconate attenuates dextran sulfate sodium-induced ulcerative colitis in BALB/c mice: investigations on the TXNIP/NLRP3 inflammasome signaling pathway.
Tiwari P, Aabis M, Kumar V, et al. · Inflammopharmacology 2026
Also in development for Knee Osteoarthritis
- EcnoglutideXW003, VRB-101Phase 38 trials
Hangzhou Sciwind Biosciences Co., Ltd. · Obesity, Weight Management, OSA - Obstructive Sleep Apnea
- hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials
Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)
- JOINTSTEMPhase 32 trials
R-Bio · Knee Osteoarthritis, Osteoarthritis, Knee
- Reference DrugNSAIDsPhase 32 trials
SANGMYUNG innovation · Retinal Vein Occlusion With Macular Edema, Knee Osteoarthritis
- PTP-01MOTYS, allogeneic human placental tissue particulatePhase 31 trial
Doron Therapeutics Inc. · Knee Osteoarthritis
- TTAX03Phase 22 trials
BioTissue Holdings, Inc · Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
- NCR100Phase 21 trial
Nuwacell Biotechnologies Co., Ltd. · Knee Osteoarthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.